OsteoRemedies said today that it initiated the full commercial launch of its Remedy knee spacer with attachable modular stems for connecting the femoral and tibial component. The Remedy knee spacer is designed for use in a two-stage procedure in the event of permanent prosthesis infection. It is intended for temporary use in 180 days or […]
OsteoRemedies recently announced that it has received FDA clearance for its Remedy Spectrum GV hip spacer system and Spectrum GV bone cement. The system is designed to give surgeons a broad spectrum of treatment options with both Gentamicin and Vancomycin. Get the full story on our sister site, Drug Delivery Business.
Cartiva said it secured $8.5 million in an over-subscribed Series D financing for developing new products to treat cartilage injuries and osteoarthritis.
The round was led by new investor New Enterprise Assoc. and existing backer Windham Venture Partners, Cartiva said.